Lung

, Volume 185, Issue 5, pp 249–255

Efficacy of Corticosteroids in the Treatment of Community-Acquired Pneumonia Requiring Hospitalization

  • Katsunaka Mikami
  • Masaru Suzuki
  • Hiroshi Kitagawa
  • Masaki Kawakami
  • Nobuaki Hirota
  • Hiromichi Yamaguchi
  • Osamu Narumoto
  • Yoshiko Kichikawa
  • Makoto Kawai
  • Hiroyuki Tashimo
  • Hidenori Arai
  • Tadashi Horiuchi
  • Yoshio Sakamoto
Article

Abstract

Background

Recent studies suggested that administration of corticosteroids may improve clinical outcomes in patients with severe pneumonia.

Objectives

The aim of this study was to assess the effectiveness of corticosteroids as an adjunctive therapy in community-acquired pneumonia (CAP) requiring hospitalization.

Design and Setting

An open label, prospective, randomized control study was conducted from September 2003 to February 2004 in a community general hospital in Japan.

Patients

Thirty-one adult CAP patients who required hospitalization were enrolled.

Measurements and Results

Fifteen patients received 40 mg of prednisolone intravenously for 3 days (steroid group). Sixteen patients did not receive prednisolone (control group). Both groups were also evaluated for their adrenal function. The primary endpoint was length of hospital stay. Secondary endpoints were duration of intravenous (IV) antibiotics and time required to stabilize vital signs. Both groups demonstrated similar baseline characteristics and length of hospital stay, and yet a shorter duration of IV antibiotics was observed in the steroid group (p < 0.05). In addition, vital signs were stabilized earlier in the steroid group (p < 0.05). These differences were more prominent in the moderate–severe subgroup but not as significant in the mild–moderate subgroup. The prevalence of relative adrenal insufficiency (RAI) in both groups was high (43%), yet there was no difference in baseline characteristics between patients, with or without RAI. In multiple regression models, RAI seemed to have no influence on clinical courses.

Conclusions

In moderate–severe CAP, administration of corticosteroids promotes resolution of clinical symptoms and reduces the duration of intravenous antibiotic therapy.

Keywords

Community-acquired pneumonia Corticosteroids Relative adrenal insufficiency 

Abbreviations

CAP

Community-acquired pneumonia

RAI

Relative adrenal insufficiency

PSI

Pneumonia severity index

PORT

Pneumonia Patient Outcomes Research Team

References

  1. 1.
    Health and Welfare Statistics Association of Japan (2004) Annual Report of National Health and Hygiene in Japan. Kouseinoshihyou 51:382–385 [in Japanese]Google Scholar
  2. 2.
    Bartlett JG, Mundy LM (1995) Community-acquired pneumonia. N Eng J Med 333:1618–1624CrossRefGoogle Scholar
  3. 3.
    Stahl JE, Barza M, DesJardin, Martin R, Eckman MH (1999) Effect of macrolides as part of initial antibiotic therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 159:2576–2580PubMedCrossRefGoogle Scholar
  4. 4.
    Gleason PP, Meeham TP, Fine JM, Galusha DH, Fine MJ (1999) Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 159:2562–2572PubMedCrossRefGoogle Scholar
  5. 5.
    Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, Weber GF, Petrillo MK, Houck PM, Fine JM (1997) Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 278:2080–2084PubMedCrossRefGoogle Scholar
  6. 6.
    Ramirez JA, Bordon J (2001) Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med 161:848–850PubMedCrossRefGoogle Scholar
  7. 7.
    National Institutes of Health / National Heart Lung, Blood Institute (2002) Global Initiative for Asthma. Global strategy for asthma management and prevention. NIH Publ 02–3659Google Scholar
  8. 8.
    Hurd S, Pauwels R (2002) Global Initiative for Chronic Obstructive Lung Diseases (GOLD). Pulm Pharmacol Ther 15:353–355PubMedCrossRefGoogle Scholar
  9. 9.
    Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, Hemmer B, Hummel T, Lenhart A, Heyduck M, Stoll C, Peter K (1999) Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 27:723–732PubMedCrossRefGoogle Scholar
  10. 10.
    Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, Chaumet-Riffaut P, Bellissant E (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862–871PubMedCrossRefGoogle Scholar
  11. 11.
    Lebel MH, Freij BJ, Syrogiannopoulos GA, Chrane DF, Hoyt MJ, Stewart SM, Kennard BD, Olsen KD, McCracken GH Jr (1988) Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials. N Engl J Med 319:964–971PubMedCrossRefGoogle Scholar
  12. 12.
    de Gans J, van de Beek D (2002) Dexamethasone in adults with bacterial meningitis. N Engl J Med 347:1549–1556PubMedCrossRefGoogle Scholar
  13. 13.
    Monton C, Ewig S, Torres A, El-Ebiary M, Filella X, Rano A, Xaubet A (1999) Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J 14:218–220PubMedCrossRefGoogle Scholar
  14. 14.
    Confalonieri M, Urbino R, Potena A, Piattella M, Pariqi P, Puccio G, Della Porta R, Giorqio C, Blasi F, Umberqer R, Meduri GU (2005) Hydrocortisone infusion for severe community-acquired pneumonia. Am J Respir Crit Care Med 171:242–248PubMedCrossRefGoogle Scholar
  15. 15.
    Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL (2001) American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163:1730–1754PubMedGoogle Scholar
  16. 16.
    Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336:243–250PubMedCrossRefGoogle Scholar
  17. 17.
    Cooper MS, Stewart PM (2003) Corticosteroid insufficiency in acutely ill patients. N Engl J Med 348:727–734PubMedCrossRefGoogle Scholar
  18. 18.
    Slutsky AS, Tremblay LN (1998) Multiple system organ failure. Is mechanical ventilation a contributing factor? Am J Respir Crit Care Med 157:1721–1725PubMedGoogle Scholar
  19. 19.
    Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, Anderson P, Morgan NA (1999) Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 340:1941–1947PubMedCrossRefGoogle Scholar
  20. 20.
    Bach PB, Brown C, Gelfand SE, McCrory DC (2001) American College of Physicians–American Society of Internal Medicine; American College of Chest Physicians. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med 134:600–620PubMedGoogle Scholar
  21. 21.
    File TM Jr (2004) Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin Infect Dis 39:S159–S164PubMedCrossRefGoogle Scholar
  22. 22.
    Mandell LA, File TM Jr (2003) Short-course treatment of community-acquired pneumonia. Clin Infect Dis 37:761–763PubMedCrossRefGoogle Scholar
  23. 23.
    Sibille Y, Reynolds HY (1990) Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis 141:471–501PubMedGoogle Scholar
  24. 24.
    Dehoux MS, Boutten A, Ostinelli J, Seta N, Dombret MC, Crestani B, Deschenes M, Trouillet JL, Aubier M (1994) Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 150:710–716PubMedGoogle Scholar
  25. 25.
    Puren AJ, Feldman C, Savage N, Becker PJ, Smith C (1995) Patterns of cytokine expression in community-acquired pneumonia. Chest 107:1342–1349PubMedGoogle Scholar
  26. 26.
    Maus U, Rosseau S, Knies U, Seeger W, Lohmeyer J (1998) Expression of pro-inflammatory cytokines by flow-sorted alveolar macrophages in severe pneumonia. Eur Respir J 11:534–541PubMedGoogle Scholar
  27. 27.
    Marik PE, Zaloga GP (2002) Adrenal insufficiency in the critically ill: a new look at an old problem. Chest 122:1784–1796PubMedCrossRefGoogle Scholar
  28. 28.
    Salluh JI, Verdeal JC, Mello GW, Araujo LV, Martins GA, de Sousa Santino M, Soares M (2006) Cortisol levels in patients with severe community-acquired pneumonia. Intensive Care Med 32:595–598PubMedCrossRefGoogle Scholar
  29. 29.
    Stuck AE, Minder CE, Frey FJ (1989) Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 11:954–963PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Katsunaka Mikami
    • 1
  • Masaru Suzuki
    • 1
  • Hiroshi Kitagawa
    • 1
  • Masaki Kawakami
    • 1
  • Nobuaki Hirota
    • 1
  • Hiromichi Yamaguchi
    • 1
  • Osamu Narumoto
    • 1
  • Yoshiko Kichikawa
    • 1
  • Makoto Kawai
    • 1
  • Hiroyuki Tashimo
    • 1
  • Hidenori Arai
    • 1
  • Tadashi Horiuchi
    • 1
  • Yoshio Sakamoto
    • 1
  1. 1.Department of Internal MedicineKanto Central HospitalTokyoJapan

Personalised recommendations